General Information
Derived from needles of yew trees, cabazitaxel is prescribed for the treatment of patients with hormone-refractory prostate cancer (HRPC) that has spread to other parts of the body and was previously treated with a docetaxel-containing treatment regimen. It is used in combination with prednisone. HRPC is a prostate cancer that has become unresponsive to hormonal manipulation.Cabazitaxel is administered intravenously.
About the API
Systematic name
(2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tertbutoxycarbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate – propan-2-one (1
Trade name(s)
Jevtana
Technology
Synthetic
Molecular Formula
C45H57NO14.C3H6O
Molecular Weight
894.01 g/mol
Physical properties
White to almost-white powder
Therapeutic category
Oncology
Available formulations
Injectables
Regulations
Canada DMF
CEP
EU DMF
US DMF
Canada DMF
CEP
EU DMF
US DMF